- Home
- TEI vs SERA Comparison
TEI vs SERA Comparison
Compare TEI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEI
- SERA
- Stock Information
- Founded
- TEI 1993
- SERA 2008
- Country
- TEI United States
- SERA United States
- Employees
- TEI N/A
- SERA N/A
- Industry
- TEI Finance Companies
- SERA Precision Instruments
- Sector
- TEI Finance
- SERA Health Care
- Exchange
- TEI Nasdaq
- SERA Nasdaq
- Market Cap
- TEI 253.1M
- SERA 258.3M
- IPO Year
- TEI N/A
- SERA 2021
- Fundamental
- Price
- TEI $5.80
- SERA $7.21
- Analyst Decision
- TEI
- SERA
- Analyst Count
- TEI 0
- SERA 0
- Target Price
- TEI N/A
- SERA N/A
- AVG Volume (30 Days)
- TEI 142.4K
- SERA 140.4K
- Earning Date
- TEI 01-01-0001
- SERA 11-06-2024
- Dividend Yield
- TEI 10.51%
- SERA N/A
- EPS Growth
- TEI N/A
- SERA N/A
- EPS
- TEI N/A
- SERA N/A
- Revenue
- TEI N/A
- SERA $107,000.00
- Revenue This Year
- TEI N/A
- SERA N/A
- Revenue Next Year
- TEI N/A
- SERA $2,020.00
- P/E Ratio
- TEI N/A
- SERA N/A
- Revenue Growth
- TEI N/A
- SERA N/A
- 52 Week Low
- TEI $4.35
- SERA $1.56
- 52 Week High
- TEI $5.39
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- TEI 52.84
- SERA 46.26
- Support Level
- TEI $5.80
- SERA $6.87
- Resistance Level
- TEI $5.90
- SERA $8.19
- Average True Range (ATR)
- TEI 0.07
- SERA 0.50
- MACD
- TEI -0.01
- SERA -0.06
- Stochastic Oscillator
- TEI 17.65
- SERA 25.00
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments and Money Market Funds.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.